低剂量拉多替吉治疗轻度认知障碍的2期安慰剂对照试验
结果显示拉多替吉安全耐受,但未显著延缓痴呆进展,却与全脑和海马体积丢失减少相关。
要点
- 拉多替吉10 mg/d在轻度认知障碍患者中安全且耐受良好。
- 拉多替吉未显著降低进展为阿尔茨海默病痴呆的风险。
- 拉多替吉与全脑和海马体积丢失减少相关,提示可能影响萎缩。
核心结论
- 拉多替吉安全且耐受良好,但未延缓轻度认知障碍患者进展为痴呆。
- 拉多替吉与全脑和海马体积丢失减少相关,提示对萎缩可能有潜在影响。
研究设计与样本
- 3年随机双盲安慰剂对照2期临床试验,纳入55至85岁伴内侧颞叶萎缩的轻度认知障碍患者。
- 主要结局为安全性和阿尔茨海默病痴呆起病,次要结局包括神经心理测验组合 composite、痴呆残疾评估和老年抑郁量表评分。
主要发现
- 36个月后,安慰剂组103例中21例、拉多替吉组99例中14例进展为阿尔茨海默病痴呆(log-rank检验 p = 0.162)。
- 神经心理测验组合 composite、痴呆残疾评估和老年抑郁量表评分均无显著影响。
- 全脑和海马体积在安慰剂组下降多于拉多替吉组(全脑 p = 0.025,Cohen d = 0.43;海马 p = 0.043,d = 0.43)。
- 严重不良事件在安慰剂组107例中28例报告,拉多替吉组103例中26例报告。
关键数值与推荐
- 入组标准包括临床痴呆评定量表评分0.5、简易精神状态检查评分>24、韦氏记忆量表修订版言语配对联想I评分≤18、内侧颞叶萎缩量表评分>1。
- 主要结局指标为安全性和阿尔茨海默病痴呆起病。
- 探索性结局包括神经心理测验组合各成分、临床痴呆评定量表和简易精神状态检查评分。
- 生物标志物包括MRI衍生的全脑、海马和内嗅皮层体积。
临床怎么用
- 拉多替吉10 mg/d在此试验中安全耐受,但未显示延缓痴呆进展的疗效。
- 全脑和海马体积丢失减少的发现提示需进一步研究其对脑萎缩的潜在作用。
- 该研究提供II级证据表明拉多替吉未显著降低伴内侧颞叶萎缩的轻度认知障碍患者发展为阿尔茨海默病的风险。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Ladostigil reduces oxidative stress and microglial activation in aging rats. We assessed its safety and potential efficacy in a 3-year, randomized, double-blind, placebo-controlled phase 2 clinical trial in patients with mild cognitive impairment (MCI) and medial temporal lobe atrophy. METHODS: Patients 55 to 85 years of age with MCI, Clinical Dementia Rating (CDR) score of 0.5, Mini-Mental State Examination (MMSE) score >24, Wechsler Memory Scale-Revised Verbal Paired Associates I score ≤18, and Medial Temporal Lobe Atrophy Scale score >1 were stratified by APOE ε4 genotype and randomly assigned (1:1) to ladostigil 10 mg/d or placebo. Primary outcomes were safety and onset of Alzheimer disease dementia. Secondary endpoints were Neuropsychological Test Battery (NTB) composite, Disability Assessment in Dementia (DAD), and Geriatric Depression Scale (GDS) scores. Exploratory outcomes were NTB component, CDR, and MMSE scores. Biomarkers included MRI-derived whole-brain, hippocampus, and entorhinal cortex volumes. RESULTS: Two hundred ten patients from 15 sites in Austria, Germany, and Israel were randomly allocated to placebo (107 patients) or ladostigil (103 patients). After 36 months, 21 of 103 patients on placebo and 14 of 99 patients receiving ladostigil progressed to Alzheimer disease (log-rank test p = 0.162). There were no significant effects on the NTB composite, DAD, or GDS score. Whole-brain and hippocampus volumes decreased more in the placebo than in the ladostigil group (whole brain, p = 0.025, Cohen d = 0.43; hippocampus, p = 0.043, d = 0.43). Serious adverse events were reported by 28 of 107 patients treated with placebo and 26 of 103 with ladostigil. CONCLUSION: Ladostigil was safe and well tolerated but did not delay progression to dementia. Its association with reduced brain and hippocampus volume loss suggests a potential effect on atrophy. CLINICALTRIALSGOV IDENTIFIER: NCT01429623. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for patients with MCI and medial temporal lobe atrophy, ladostigil did not significantly decrease the risk of the development of Alzheimer disease.
引用
- Schneider LS, Geffen Y, Rabinowitz J, et al. Low-dose ladostigil for mild cognitive impairment: A phase 2 placebo-controlled clinical trial. Neurology. 2019. PMID: 31492718. doi:10.1212/WNL.0000000000008239
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。